Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cinclus Pharma Holding ABFRA:J8P -2.13%6 PS Ratio is 7.65 as of Jul. 15, 2026, which is 63% below its 10-year median of 20.84. GuruFocus rates FRA:J8P with a GF Score™ of 6/100. The stock has 3 warning signs investors should review. Among 955 Drug Manufacturers companies, Cinclus Pharma Holding AB ranks worse than 83.14% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Cinclus Pharma Holding AB's share price is €1.01.
Cinclus Pharma Holding AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €0.13. Hence, Cinclus Pharma Holding AB's PS Ratio for today is 7.65.
Good Sign:
Cinclus Pharma Holding AB stock PS Ratio (=8.1) is close to 3-year low of 7.54.
The historical rank and industry rank for Cinclus Pharma Holding AB's PS Ratio or its related term are showing as below:
FRA:J8P'
s PS Ratio Range Over the Past 10 Years
Min: 7.54 Med: 20.84 Max: 502.94
Current: 7.93
During the past 5 years, Cinclus Pharma Holding AB's highest PS Ratio was 502.94. The lowest was 7.54. And the median was 20.84.
FRA:J8P's PS Ratio is ranked worse than 83.14% of 955
companies
in the Drug Manufacturers industry
Industry Median: 2.35
vs FRA:J8P: 7.93
During the past 5 years, Cinclus Pharma Holding AB's highest 3-Year average Revenue per Share Growth Rate was 71.60% per year. The lowest was 71.60% per year. And the median was 71.60% per year.
Back to Basics: PS Ratio
Cinclus Pharma Holding AB (FRA:J8P) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Cinclus Pharma Holding AB PS Ratio Related Terms
Cinclus Pharma Holding AB PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cinclus Pharma Holding AB's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cinclus Pharma Holding AB PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cinclus Pharma Holding AB's PS Ratio distribution charts can be found below:
* The bar in red indicates where Cinclus Pharma Holding AB's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Cinclus Pharma Holding AB's Share Price of today is €1.01. Cinclus Pharma Holding AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.13.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Cinclus Pharma Holding AB (FRA:J8P) has a PS Ratio of 7.65 as of Jul. 15, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Cinclus Pharma Holding AB and its competitors. This is 63% below median its historical median of 20.84. Over the past decade, Cinclus Pharma Holding AB's PS Ratio has ranged from 7.54 to 502.94. According to the industry distribution chart, Cinclus Pharma Holding AB ranks #794 out of 955 companies in the Drug Manufacturers industry, placing it in the top 83.1%.
Is Cinclus Pharma Holding AB's PS Ratio too high?
Cinclus Pharma Holding AB's current PS Ratio of 7.65 is 63% below median its 10-year median of 20.84. Over the past 10 years, this metric has ranged from a low of 7.54 to a high of 502.94. The Drug Manufacturers industry median PS Ratio is 2.35. Cinclus Pharma Holding AB's value of 7.65 is 225.5% above this industry median. Based on the distribution chart, Cinclus Pharma Holding AB ranks #794 out of 955 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Cinclus Pharma Holding AB has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Cinclus Pharma Holding AB's PS Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cinclus Pharma Holding AB ranks #794 out of 955 companies for PS Ratio. This places Cinclus Pharma Holding AB in the lower half of its industry. The industry median PS Ratio is 2.35. Cinclus Pharma Holding AB's value of 7.65 is 225.5% above this benchmark. Historically, Cinclus Pharma Holding AB's own PS Ratio has ranged from 7.54 to 502.94 over the past decade. While the company's 10-year median is 20.84 vs. the industry median of 2.35, Cinclus Pharma Holding AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.35, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cinclus Pharma Holding AB's current PS Ratio of 7.65 is 225.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Cinclus Pharma Holding AB and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cinclus Pharma Holding AB's current PS Ratio is 7.65, which is 63% below median its own 10-year median of 20.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cinclus Pharma Holding AB stock overvalued right now?
Cinclus Pharma Holding AB (FRA:J8P) has a current PS Ratio of 7.65. The current PS Ratio is 7.65, which is 63% below median its 10-year median of 20.84 and 225.5% above the Drug Manufacturers industry median of 2.35. Cinclus Pharma Holding AB's overall GF Score™ is 6/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Cinclus Pharma Holding AB (FRA:J8P), the current PS Ratio is 7.65 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cinclus Pharma Holding AB is a Swedish clinical-stage pharmaceutical company focused on developing small-molecule treatments for gastric acid-related diseases. Its candidate, linaprazan glurate, is being developed for the treatment of severe gastroesophageal reflux disease, including erosive forms. The company is also developing a dual therapy treatment with an antibiotic targeting Helicobacter pylori, a bacterium found in the gastric and duodenal mucosa. Its primary target population consists of patients with severe erosive gastroesophageal reflux disease, where current treatment options are limited. It operates in Switzerland, Sweden, and the Czech Republic, with the majority of revenue from the Czech Republic.
6GF Score
Get the complete analysis for FRA:J8P
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:J8P has been successfully added to your 
